Bausch Health Companies Inc (BHC)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $3.13B
Last updated: Nov 17, 2026 at 11:05 AM ET
Bausch Health Companies Inc (BHC) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Bausch Health Companies reported EPS of $1.77, above the $1.08 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
Analysts' consensus for the quarter ending Dec 31, 2026 is 28.7% above the $1.08 reported for the quarter ended Dec 31, 2025.
BHC's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
BHC Earnings Call
The latest BHC earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, BHC beat 30 and missed 10. Revenue for the quarter ended Sep 30, 2026 was $2.94B, up 9.7% from $2.68B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.77 | $1.08 | N/A | +63.89% | Beat | +52.6% | 6 | 1 up, 0 down | Oct 28, 2026 | $2.94B |
| Jun 30, 2026 | $1.26 | $0.96 | $0.93 - $1.20 | +31.25% | Beat | +38.5% | 5 | 2 up, 0 down | Jul 29, 2026 | $2.85B |
| Mar 31, 2026 | $0.78 | $0.69 | $0.48 - $0.87 | +13.04% | Beat | +27.9% | 7 | 0 up, 1 down | Apr 29, 2026 | $2.52B |
| Dec 31, 2025 | $1.08 | $1.21 | $1.13 - $1.39 | -10.74% | Miss | -6.9% | 6 | 0 up, 1 down | Feb 18, 2026 | $2.80B |
| Sep 30, 2025 | $1.16 | $1.06 | $0.81 - $1.18 | +9.43% | Beat | +2.7% | 5 | 2 up, 0 down | Oct 29, 2025 | $2.68B |
| Jun 30, 2025 | $0.91 | $0.94 | $0.82 - $1.10 | -3.19% | Miss | -7.1% | 5 | 1 up, 0 down | Jul 30, 2025 | $2.53B |
| Mar 31, 2025 | $0.61 | $0.85 | $0.72 - $1.06 | -28.24% | Miss | +3.4% | 5 | 1 up, 1 down | Apr 30, 2025 | $2.26B |
| Dec 31, 2024 | $1.16 | $1.13 | $0.90 - $1.37 | +2.96% | Beat | +0.9% | 6 | 2 up, 1 down | Feb 19, 2025 | $2.56B |
| Sep 30, 2024 | $1.13 | $1.02 | $0.92 - $1.16 | +10.78% | Beat | +9.7% | 7 | 1 up, 1 down | Oct 30, 2024 | $2.51B |
| Jun 30, 2024 | $0.98 | $0.88 | $0.79 - $1.00 | +11.36% | Beat | +21.0% | 6 | 0 up, 1 down | Aug 1, 2024 | $2.40B |
| Mar 31, 2024 | $0.59 | $0.72 | $0.59 - $0.85 | -18.06% | Miss | +11.3% | 5 | 1 up, 0 down | May 2, 2024 | $2.15B |
| Dec 31, 2023 | $1.15 | $1.02 | $0.99 - $1.11 | +12.75% | Beat | +11.7% | 6 | 1 up, 1 down | Feb 22, 2024 | $2.41B |
| Sep 30, 2023 | $1.03 | $0.92 | $0.82 - $1.02 | +11.96% | Beat | +35.5% | 5 | 1 up, 1 down | Nov 2, 2023 | $2.24B |
| Jun 30, 2023 | $0.81 | $0.73 | $0.64 - $0.85 | +10.96% | Beat | +47.3% | 6 | 0 up, 1 down | Aug 3, 2023 | $2.17B |
| Mar 31, 2023 | $0.53 | $0.68 | $0.63 - $0.84 | -22.06% | Miss | -26.4% | 5 | 0 up, 0 down | May 4, 2023 | $1.94B |
| Dec 31, 2022 | $1.03 | $0.95 | $0.73 - $1.11 | +8.42% | Beat | -19.5% | 6 | 0 up, 1 down | Feb 23, 2023 | $2.19B |
| Sep 30, 2022 | $0.76 | $0.78 | N/A | -2.56% | Miss | -33.9% | 7 | 0 up, 2 down | Nov 3, 2022 | $2.05B |
| Jun 30, 2022 | $0.55 | $0.91 | $0.79 - $1.00 | -39.56% | Miss | -43.3% | 7 | 0 up, 0 down | Aug 9, 2022 | $1.97B |
| Mar 31, 2022 | $0.72 | $1.03 | N/A | -30.10% | Miss | -29.4% | 5 | 0 up, 1 down | May 10, 2022 | $1.92B |
| Dec 31, 2021 | $1.28 | $1.12 | N/A | +14.29% | Beat | -3.8% | 7 | 1 up, 0 down | Feb 23, 2022 | $2.20B |
| Sep 30, 2021 | $1.15 | $1.06 | $1.01 - $1.10 | +8.49% | Beat | -12.2% | 9 | 0 up, 1 down | Nov 2, 2021 | $2.11B |
| Jun 30, 2021 | $0.97 | $0.95 | $0.80 - $1.04 | +2.11% | Beat | +110.9% | 9 | N/A | Aug 3, 2021 | $2.10B |
| Mar 31, 2021 | $1.02 | $0.95 | $0.83 - $1.07 | +7.37% | Beat | +14.6% | 10 | N/A | May 4, 2021 | $2.03B |
| Dec 31, 2020 | $1.33 | $1.12 | $0.88 - $1.38 | +18.75% | Beat | +15.7% | 14 | N/A | Feb 24, 2021 | N/A |
| Sep 30, 2020 | $1.31 | $1.04 | $0.87 - $1.28 | +25.96% | Beat | +8.3% | 15 | N/A | Nov 3, 2020 | $2.14B |
| Jun 30, 2020 | $0.46 | $0.65 | $0.41 - $0.86 | -29.23% | Miss | -57.0% | 15 | N/A | Aug 6, 2020 | $1.66B |
| Mar 31, 2020 | $0.89 | $0.88 | $0.75 - $0.99 | +1.14% | Beat | -13.6% | 15 | N/A | May 7, 2020 | $2.01B |
| Dec 31, 2019 | $1.15 | $1.13 | $0.99 - $1.45 | +1.77% | Beat | +11.7% | 15 | N/A | Feb 19, 2020 | $2.22B |
| Sep 30, 2019 | $1.21 | $1.09 | $0.97 - $1.30 | +11.01% | Beat | +5.2% | 15 | N/A | Nov 4, 2019 | $2.21B |
| Jun 30, 2019 | $1.07 | $1.06 | $0.94 - $1.14 | +0.94% | Beat | +15.1% | 14 | N/A | Aug 6, 2019 | $2.15B |
| Mar 31, 2019 | $1.03 | $0.86 | $0.75 - $0.97 | +19.77% | Beat | +17.0% | 14 | N/A | May 6, 2019 | $2.02B |
| Dec 31, 2018 | $1.03 | $0.84 | $0.60 - $1.01 | +22.62% | Beat | +5.1% | 13 | N/A | Feb 20, 2019 | $2.12B |
| Sep 30, 2018 | $1.15 | $0.86 | $0.56 - $0.93 | +33.72% | Beat | +10.6% | 13 | N/A | Nov 6, 2018 | $2.14B |
| Jun 30, 2018 | $0.93 | $0.80 | N/A | +16.25% | Beat | -11.4% | N/A | N/A | Aug 7, 2018 | $2.13B |
| Mar 31, 2018 | $0.88 | $0.60 | N/A | +46.67% | Beat | +12.8% | N/A | N/A | May 8, 2018 | $2.00B |
| Dec 31, 2017 | $0.98 | $0.97 | N/A | +1.03% | Beat | -22.2% | N/A | N/A | Feb 28, 2018 | $2.16B |
| Sep 30, 2017 | $1.04 | $0.89 | N/A | +16.85% | Beat | -32.9% | N/A | N/A | Nov 7, 2017 | $2.22B |
| Jun 30, 2017 | $1.05 | $0.96 | N/A | +9.38% | Beat | -25.0% | N/A | N/A | Aug 8, 2017 | $2.23B |
| Mar 31, 2017 | $0.78 | $0.82 | N/A | -4.88% | Miss | -38.6% | N/A | N/A | May 9, 2017 | $2.11B |
| Dec 31, 2016 | $1.26 | $1.20 | N/A | +5.00% | Beat | -49.6% | N/A | N/A | Feb 28, 2017 | $2.40B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $3.76, down 2.6% from the year before. It was $5.48 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $3.76 | -2.6% |
| Dec 31, 2024 | $3.86 | +9.7% |
| Dec 31, 2023 | $3.52 | +15.0% |
| Dec 31, 2022 | $3.06 | -30.8% |
| Dec 31, 2021 | $4.42 | +10.8% |
| Dec 31, 2020 | $3.99 | -10.5% |
| Dec 31, 2019 | $4.46 | +11.8% |
| Dec 31, 2018 | $3.99 | +3.6% |
| Dec 31, 2017 | $3.85 | -29.7% |
| Dec 31, 2016 | $5.48 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,500 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,464 | 7 | |
| 2026Q2 | Jun 30, 2026 | 5,225 | 8 | |
| 2026Q1 | Mar 31, 2026 | 5,902 | 9 | |
| 2025Q4 | Dec 31, 2025 | 6,503 | 10 | |
| 2025Q3 | Sep 30, 2025 | 5,938 | 11 | |
| 2025Q2 | Jun 30, 2025 | 4,931 | 8 | |
| 2025Q1 | Mar 31, 2025 | 6,594 | 9 | |
| 2024Q4 | Dec 31, 2024 | 6,652 | 10 |
2026Q3 Earnings Call
Opening remarks
Garen Sarafian Vice President of Investor Relations Good afternoon, and welcome to Bausch Health's third quarter 2026 Earnings Conference Call. My name is Garen Sarafian, Vice President of Investor Relations. Participating in today's call are Thomas J. Appio, Chief Executive Officer; Jean-Jacques Charhon, Chief Financial Officer; and Jonathan Sadeh, Chief Medical Officer and Head of Research and Development. Before we begin, I would like to remind you that today's presentation contains forward-looking information. Please take a moment to review the forward-looking statements disclaimer at the beginning of the slides accompanying this presentation. It contains important information. Actual results may differ materially from those expressed or implied in these forward-looking statements, and you should not place undue reliance on them. Please also refer to our SEC filings and our filings with the Canadian Securities Administrators for a discussion of certain risk factors that could cause actual results to differ materially from expectations. We use non-GAAP financial measures to help investors better understand our operating performance. These non-GAAP measures may not be comparable to similarly titled measures used by other companies and should be considered in addition to, and not as a substitute for, measures calculated in accordance with GAAP. Reconciliations to our non-GAAP measures are included in the appendix of the slides accompanying this presentation, which are also available on Bausch Health's Investor Relations website. Finally, financial guidance in this presentation is effective as of today only. We do not undertake any obligation to update guidance. Our discussion today, Wednesday, October 28, will focus on Bausch Health excluding Bausch + Lomb. However, we will briefly comment on Bausch + Lomb's results announced this morning. We will refer to year-over-year comparisons with the same period last year unless otherwise noted. With that, I will turn the call over to our CEO, Tom Appio. Tom?
Thomas J. Appio CEO Thank you, Garen, and thank you to everyone joining us today. Before I discuss our third-quarter results, I want to briefly address my recent appointment as interim CEO of Bausch + Lomb. I am honored and energized to serve as interim CEO. Having spent a good part of my career with the company, I have developed a deep understanding of its business, markets, products, and, most importantly, the exceptional global team that drives its success. Having said that, I want to reiterate that I remain fully committed to Bausch Health and all its stakeholders. I am proud of our 7,000 colleagues around the world and all that we continue to achieve together. Both companies have experienced teams and well-defined operating priorities, allowing us to remain focused on execution across each business.
Frequently Asked Questions About BHC
Did BHC beat earnings estimates last quarter?
Yes. Bausch Health Companies reported EPS of $1.77 for the quarter ended Sep 30, 2026, above the $1.08 estimate, a 63.89% surprise.
What EPS do analysts expect from BHC next quarter?
The consensus EPS estimate for Bausch Health Companies for the quarter ending Dec 31, 2026 is $1.39 from 4 analysts, with estimates from $1.21 to $1.56.
How often does BHC beat earnings estimates?
Bausch Health Companies beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +9.80%.
BHC pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors